GET DAILY SIGNALSInvivyd (IVVD): Analyst Consensus at $10 Points to +1,600% Upside Potential
Key Takeaways
- The central price target is $10, derived as the arithmetic mean of three verified analyst price targets, all currently set at $10.
- With shares recently trading near $0.59, reaching $10 would require an upside of roughly 1,600% — an extraordinarily large move.
- The three covering firms — BTIG, H.C. Wainwright, and Cantor Fitzgerald — are unanimous at $10, so there is no meaningful low-to-high range among current targets.
- The strongest support comes from the lead candidate VYD2311, a COVID-19 monoclonal antibody, and its pivotal DECLARATION Phase 3 readout expected in the third quarter of 2026.
- The biggest risks are continued net losses, the pending expiry of PEMGARDA's emergency authorization, and the threat of a Nasdaq delisting for a low bid price.
Analyst Consensus and Uniform Targets
Invivyd, Inc. (IVVD) is a clinical-stage biopharmaceutical company focused on monoclonal antibody therapies for infectious diseases, particularly COVID-19. Coverage remains limited yet remarkably consistent. Three analysts maintain targets at $10 per share: Thomas Shrader at BTIG (Buy, reiterated September 2026), Patrick Trucchio at H.C. Wainwright (Buy, reiterated September 2026), and Joshua Schimmer at Cantor Fitzgerald (Overweight, reiterated September 2026). I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
With every verified target identical at $10, the arithmetic mean lands exactly there, and the rounded central target is $10. The lack of spread between high and low targets stands out as unusual. An earlier downgrade by D. Boral Capital to Hold in November 2025 lacks a current price target in the reviewed data. Analysts’ optimism centers on VYD2311 and the upcoming DECLARATION Phase 3 readout. This $10 figure reflects the calculated mean of verified targets rather than any guarantee, and it implies a move far larger than typical forecasts.
Current Market Position and Required Move
Shares of Invivyd, Inc. (IVVD) have traded near $0.59, well below the 52-week high of roughly $3.07 and close to the low near $0.53. From the recent price, a $10 target would require an upside of approximately 1,600%, a very large move by any standard. The path outlined by analysts hinges primarily on clinical and regulatory milestones rather than current financial performance. The company reported about $14.3 million in revenue for the second quarter of 2026 alongside a GAAP net loss of roughly $44.4 million. Positive topline results from the LIBERTY Phase 3 study, released in September 2026, indicated that VYD2311’s safety and tolerability compared favorably with an mRNA COVID-19 vaccine, and the company intends to pursue a Biologics License Application under the FDA’s accelerated approval pathway once DECLARATION data arrive.
Potential Catalysts for Progress
- A successful DECLARATION Phase 3 readout for VYD2311, expected in Q3 2026, could support a BLA filing and speed the regulatory timeline.
- The LIBERTY study’s favorable safety profile, with no anaphylaxis and no Grade 3-plus VYD2311-related events, bolsters the clinical foundation.
- Analysts have repeatedly reaffirmed their $10 price targets, indicating continued confidence in the key catalyst despite the low share price.
- PEMGARDA, the company’s commercial COVID-19 antibody, generated about $53.4 million in net product revenue in 2025, more than double the prior year and showing demand among immunocompromised patients.
Key Risks to Consider
- The company continues to post significant net losses and depends on a single commercial product plus a focused clinical pipeline.
- PEMGARDA’s emergency use authorization expires on June 29, 2027, unless full approval is obtained, creating a clear regulatory overhang.
- Invivyd, Inc. (IVVD) received a Nasdaq notice for a bid price deficiency in July 2026, raising delisting concerns that could affect financing and valuation.
- A disappointing or delayed DECLARATION readout would likely weaken the central thesis, given the stock’s heavy reliance on VYD2311.
Technical Context and Levels to Watch
From a technical perspective, the stock trades near the bottom of a steep multi-month downtrend. The 52-week high near $3.07 remains a distant reference, while recent activity has stayed compressed in the $0.53 to $0.60 area. Any sustained recovery would first need to reclaim the $1 level, a meaningful threshold even if it falls well short of the $10 target. The wide gap to the target shifts focus toward avoiding delisting pressure rather than mapping a direct route to $10.
Time Horizon and Monitoring Points
Analyst price targets typically cover a roughly 12-month horizon, though exact timeframes are not always specified. Given the catalyst-driven profile, investors should track the DECLARATION Phase 3 results, any BLA submission or FDA feedback, updates on PEMGARDA’s full-approval path, quarterly cash burn and financing moves, and Nasdaq delisting proceedings. These events will shape whether the share price can begin to narrow the substantial distance to the $10 target.
Using AI Tools in Research
I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. For a highly volatile, catalyst-driven name like Invivyd, Inc. (IVVD), these signals can help traders spot changing trends and potential turning points more efficiently than manual chart review. Traders can use them to discover new opportunities, monitor existing positions, and stay alert to shifts in momentum.
Final Assessment
Whether Invivyd, Inc. (IVVD) can reach $10 is best viewed as a clinical-binary question rather than a standard valuation exercise. The central target is the arithmetic mean of three verified analyst targets, all set at $10, implying a required move of roughly 1,600% from the recent price near $0.59 — a very large move by any measure. Support rests on a favorable DECLARATION readout and an accelerated approval pathway for VYD2311, while the main obstacles remain continued losses, the PEMGARDA authorization expiry, and delisting risk. Analyst coverage is unanimous at $10, which provides conviction but little diversity of opinion. Investors should monitor the pivotal trial data and regulatory developments rather than treat the target as a probability. No outcome is guaranteed.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IVVD's RSI Indicator ascends from oversold territory
The RSI Indicator for IVVD moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 46 similar instances when the indicator left oversold territory. In 43 of the 46 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where IVVD advanced for three days, in 186 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IVVD as a result. In 65 of 72 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for IVVD turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 35 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
IVVD moved below its 50-day moving average on October 07, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IVVD crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IVVD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IVVD entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.958) is normal, around the industry mean (2.974). P/E Ratio (-1.899) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (3.722) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. IVVD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IVVD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement